STOCK TITAN
  1. Home
  2. News
  3. COYA

Coya Therapeutics, Inc. - COYA STOCK NEWS

Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.

Coya Therapeutics, Inc. (symbol: COYA) is a clinical-stage biotechnology company dedicated to pioneering therapies that regulate the function of regulatory T cells (Tregs). The company focuses on developing novel and proprietary medicinal products aimed at modulating Tregs to treat a range of debilitating diseases, including neurodegenerative, autoimmune, and metabolic disorders.

With a strong emphasis on scientific innovation, Coya Therapeutics is engaged in multi-modality Treg therapies designed to address unmet medical needs in these critical areas. By harnessing the power of Tregs, the company aims to restore immune balance and bring new hope to patients suffering from conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

In recent developments, Coya Therapeutics has made significant strides in its research and development programs, advancing its pipeline of therapeutic candidates. The company is currently engaged in multiple clinical trials to evaluate the safety and efficacy of its Treg-targeted treatments. These efforts are supported by a robust financial condition, strategic partnerships, and collaborations with leading research institutions and healthcare organizations.

Coya Therapeutics' commitment to scientific excellence and patient well-being positions it as a key player in the biotechnology sector. Investors and stakeholders can look forward to updates on clinical trial progress, new product developments, and potential market launches that underscore the company's growth trajectory and impact on the healthcare landscape.

Stay tuned to Coya Therapeutics' news releases and financial reports for the latest information on the company's achievements and future directions.

News

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Rhea-AI Summary
4-Hydroxynonenal (4-HNE) levels strongly correlate with the rate of Amyotrophic Lateral Sclerosis (ALS) disease progression and patient survival, making it a potential biomarker for tracking treatment efficacy. Coya Therapeutics, Inc. (Nasdaq: COYA) presents promising biomarker data at the Society of Neuroimmune Pharmacology Conference, indicating the importance of 4-HNE in ALS pathophysiology and patient outcomes. The company plans to validate 4-HNE as a new biomarker for predicting disease progression and survival in ALS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
none
-
News

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Rhea-AI Summary
Coya Therapeutics presents data demonstrating compromised Treg function and increased inflammatory markers in FTD patients. COYA 302 aims to restore Treg function and target inflammation in neurodegenerative diseases like FTD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
-
News

Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference

Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces the presentation of data on chronic systemic inflammation and dysfunctional Tregs in Frontotemporal Dementia patients at the AD/PD 2024 Conference. Dr. Alireza Faridar will showcase the role of the immune system in FTD pathology, funded by a grant from Houston Methodist. Coya plans to file an IND for COYA 302, a therapeutic candidate, in 4Q24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
conferences
News

Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference

Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) presents novel biomarker data in ALS patients correlating to disease progression and survival. Dr. Stanley Appel to present at the Society of Neuroimmune Pharmacology Conference on March 12th, 2024, highlighting the potential of the oxidative stress biomarker candidate. The company aims to enhance Treg function with biologics, offering new insights for patient monitoring and therapy efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
-
News

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”

Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) expands COYA 302 pipeline into Alzheimer's Disease, leveraging synergistic mode of action with LD IL-2 and CTLA4-Ig. The partnership with Dr. Reddy's Laboratories in ALS is valued at up to $733 million. Ongoing double-blind trial for LD IL-2 in AD aims to support COYA 302 development. The company plans to file INDs for ALS and FTD in 2024, with additional clinical updates and expansion of combination therapies beyond COYA 302.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
-
News

Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases

Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) expands patent estate with a license from University of Nebraska Medical Center for multiple low dose interleukin-2 (ld IL-2) combinations, including ld IL-2 + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). The combination results in a 4-6 fold synergistic increase in Tregs, enhancing Treg function and lowering inflammation. UNeMed will receive payments and royalties. The license strengthens Coya's multi-pathway approach in developing immunomodulatory drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
none
News

Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference

Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces that Dr. Stanley Appel will present at the Society of Neuroimmune Pharmacology Conference on March 11, 2024. The presentation will discuss the potential of combination immunotherapy in treating neuroinflammatory conditions like ALS, FTD, and PD. Dr. Appel will highlight the prevalence of systemic immune and inflammatory factors in ALS and the potential of COYA 302 therapy. The presentation aims to share findings on targeting multiple immunomodulatory pathways to overcome the redundancy of the immune system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
News

Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series

Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces participation in Chardan Capital Market’s biotechnology Leadership Call Series. The company's CEO, CBO, and CMO will discuss their pioneering drug development efforts in Treg-enhancing therapies for neurodegenerative diseases, specifically COYA 302. Interested investors can request attendance to the live virtual event by emailing Chardan. A replay of the session will be available on Coya’s website following the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
conferences
-
News

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Rhea-AI Summary
Coya Therapeutics, Inc. announces the expansion of its pipeline to include frontotemporal dementia and Parkinson's disease in addition to ALS. The company has developed COYA 302, a proprietary biologic combination immunotherapy targeting multiple pathways to address the proinflammatory environment underlying these diseases. The company has also provided strong and productive milestone and catalyst updates for 2024, with cash runway guidance extending into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
none
News

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Rhea-AI Summary
DISCO Pharmaceuticals, a specialist biotech company, has emerged from stealth with a transformative surfaceome discovery technology to identify new targets and develop first-in-class drugs for cancer treatment. The company has successfully raised seed financing of EUR 20 million and is backed by a world-leading investor syndicate. DISCO has completed the first-ever map of the surfaceome of Small Cell Lung Cancer and is developing proprietary antibody-based treatments for it. The company is also working on Microsatellite-Stable Colorectal Cancer and has a pipeline of further undisclosed programs. The experienced team, led by CEO Roman Thomas, includes leading biopharma executives Dieter Weinand and Carsten Reinhardt. The company's surfaceome mapping platform has the potential to transform oncology treatment options and improve outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
none

FAQ

What is the current stock price of Coya Therapeutics (COYA)?

The current stock price of Coya Therapeutics (COYA) is $5.24 as of December 20, 2024.

What is the market cap of Coya Therapeutics (COYA)?

The market cap of Coya Therapeutics (COYA) is approximately 86.9M.

What does Coya Therapeutics, Inc. specialize in?

Coya Therapeutics specializes in developing therapies that modulate regulatory T cells (Tregs) for treating neurodegenerative, autoimmune, and metabolic diseases.

What are regulatory T cells (Tregs)?

Regulatory T cells (Tregs) are a type of immune cell that helps maintain immune system balance and prevent autoimmune responses.

What types of diseases is Coya Therapeutics targeting?

The company is targeting neurodegenerative, autoimmune, and metabolic diseases such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

What are the recent achievements of Coya Therapeutics?

Recent achievements include advancements in clinical trials for their Treg therapies, strategic partnerships, and collaborations with leading research institutions.

How is Coya Therapeutics funded?

Coya Therapeutics is supported by a robust financial condition, which includes investments and collaborations with other healthcare organizations.

What is the significance of Treg therapies?

Treg therapies aim to restore immune balance, potentially offering new treatment options for diseases with limited current therapies.

Are there any ongoing clinical trials by Coya Therapeutics?

Yes, Coya Therapeutics is actively engaged in multiple clinical trials to evaluate the safety and efficacy of its Treg-targeted treatments.

Who are Coya Therapeutics' partners?

The company collaborates with leading research institutions and healthcare organizations to advance its therapeutic candidates.

What can investors expect from Coya Therapeutics?

Investors can expect updates on clinical trial progress, new product developments, and potential market launches.

How can I stay updated on Coya Therapeutics' news?

You can stay updated by following their news releases and financial reports for the latest information on achievements and future directions.

Stock COYA logo
Coya Therapeutics, Inc.

Nasdaq:COYA

COYA Rankings

#4511 Ranked by Market Cap
N/A Ranked by Dividends

COYA Stock Data

86.88M
15.04M
7.03%
19.97%
1.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HOUSTON